Alkermes plc
HealthcareNASDAQ:ALKS · NASDAQ Global Select
-$0.64 today
Vol 1.46M · Avg 2.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.3%
avg -3.6%
ROIC
10.6%
avg 0.0%
ROA
9.6%
avg -2.2%
Analysis
ROE is currently the strongest return metric at 13.3% versus its period average of -3.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard F. Pops | Chairman & Chief Executive Officer | $2.89M | — | 64 | $37,226.00 | 0.02% |
Craig C. Hopkinson | Executive Vice President of Research & Development and Chief Medical Officer | $1.42M | — | 57 | $6,356.00 | <0.01% |
Blair C. Jackson | Executive Vice President, Chief Risk Officer & Chief Operating Officer | $1.37M | — | 53 | $6,356.00 | <0.01% |
David Joseph Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary | $1.28M | — | 54 | $229,524.00 | 0.14% |
Christian Todd Nichols | Senior Vice President & Chief Commercial Officer | $1.06M | — | 56 | $109,769.00 | 0.07% |
Joshua Reed | Senior Vice President & Chief Financial Officer | $743,971.00 | — | 53 | $66,430.00 | 0.04% |
Tom Skoff | SVP & Chief Information Officer | — | — | — | — | — |
Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | — | — | — | — | — |
Declan O'Connor | Senior Vice President of Operations and Environment, Health & Safety | — | — | — | — | — |
Stephen Schiavo | Senior Vice President & Chief Human Resources Officer | — | — | — | — | — |
Samuel J. Parisi | Interim Principal Accounting Officer & Vice President of Finance | — | — | 51 | $23,934.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$6.24M
Net Sentiment
$6.24M
Net selling
Most Active
Hopkinson Craig C.
12 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $6.24M over the last 12 months. That adds up to net selling of $6.24M. Hopkinson Craig C. was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +3.0% | +10.0% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.0% over three years. Forward estimates point to Revenue at +10.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Akero Therapeutics, Inc.
AKRO
$4.50B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Who manages ALKS?
Alkermes plc (ALKS) lists 11 active executives. The top listed executive is Richard F. Pops, Chairman & Chief Executive Officer.
Are ALKS insiders buying or selling?
Recent insider activity shows net buying of $8.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.